Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V503 (Gardasil 9) in females previously vaccinated with Gardasil
NCT01047345Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2010
- Primary completion
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in Cervical Cancer (CC), vulvar cancer, vaginal cancer, genital warts, sponsored by Merck & Co.. Started Feb 2010; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Cervical Cancer (CC)vulvar cancervaginal cancergenital warts
Beyond the preview
Go deeper on NCT01047345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01047345.